Icosapent Ethyl Patent Expiration
Icosapent Ethyl is Used for reducing the risk of cardiovascular events in adult patients with elevated triglyceride levels as an adjunct to statin therapy. It was first introduced by Amarin Pharmaceuticals Ireland Ltd
Icosapent Ethyl Patents
Given below is the list of patents protecting Icosapent Ethyl, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vascepa | US10278935 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10278936 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10278937 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10383840 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10555924 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10555925 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10568861 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10576054 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10668042 | Methods of reducing the risk of cardiovascular events in a subject | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10786478 | Methods of reducing the risk of cardiovascular events in a subject | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10792270 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10894028 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US11000499 | Methods of reducing the risk of cardiovascular events in a subject | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US11116742 | Methods of reducing the risk of cardiovascular events in a subject | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US11298333 | Methods of reducing the risk of cardiovascular events in a subject | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US11369582 | Methods of reducing the risk of cardiovascular events in a subject | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US9603826 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US9610272 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US9623001 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US9693984 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US9693985 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US9693986 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US9918954 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | Jun 28, 2033 | Amarin Pharms |
| Vascepa | US10842768 | Compositions and methods for lowering triglycerides | Jun 15, 2030 | Amarin Pharms |
| Vascepa | US8410086 | Compositions and methods for lowering triglycerides | Jun 15, 2030 | Amarin Pharms |
| Vascepa | US8455472 | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | Jun 15, 2030 | Amarin Pharms |
| Vascepa | US8669245 | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | Jun 15, 2030 | Amarin Pharms |
| Vascepa | US8710041 | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy | Jun 15, 2030 | Amarin Pharms |
| Vascepa | US10010517 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US10265287 | Methods of reducing triglycerides and LDL-C | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US10792267 | Methods of treating mixed dyslipidemia | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US10842766 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US10881632 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US11103477 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US11154526 | Methods of treating mixed dyslipidemia | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US11213504 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US11717504 | Methods of reducing the risk of cardiovascular events in a subject | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8298554 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8445003 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8445013 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8454994 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8501225 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8551521 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8563608 | Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8617593 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8617594 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8618166 | Methods of treating mixed dyslipidemia | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8623406 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8642077 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8691871 | Methods of treating mixed dyslipidemia | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8703185 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US8709475 | Stable pharmaceutical composition and methods of using same | Apr 29, 2030 | Amarin Pharms |
| Vascepa | US12171738 | Compositions and methods for lowering triglycerides | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8293727 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8293728 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8314086 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8318715 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8357677 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8367652 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8377920 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8399446 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8415335 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8426399 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8431560 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8440650 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8518929 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8524698 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8546372 | Methods of treating hypertriglyceridemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US8680144 | Methods of treating mixed dyslipidemia | Feb 09, 2030 | Amarin Pharms |
| Vascepa | US9198892 | Composition and/or method for preventing onset and/or recurrence of cardiovascular events | Sep 25, 2027 | Amarin Pharms |
| Vascepa | US9700537 | Composition for preventing the occurrence of cardiovascular event in multiple risk patient | May 31, 2027 | Amarin Pharms |
| Vascepa | US8188146 | Highly purified ethyl EPA and other EPA derivatives |
Jan 27, 2020
(Expired) | Amarin Pharms |
| Vascepa | US8188146 | Highly purified ethyl EPA and other EPA derivatives |
Jan 27, 2020
(Expired) | Amarin Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Icosapent Ethyl's patents.
Latest Legal Activities on Icosapent Ethyl's Patents
Given below is the list recent legal activities going on the following patents of Icosapent Ethyl.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent | 09 Mar, 2026 | US8642077 |
| Expire Patent | 09 Feb, 2026 | US8623406 |
| Expire Patent | 02 Feb, 2026 | US8617594(Litigated) |
| Expire Patent | 02 Feb, 2026 | US8618166 |
| Expire Patent | 02 Feb, 2026 | US8617593 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Dec, 2025 | US10010517 |
| Maintenance Fee Reminder Mailed | 15 Dec, 2025 | US8709475 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Dec, 2025 | US11369582 |
| Maintenance Fee Reminder Mailed | 08 Dec, 2025 | US8703185 |
| Maintenance Fee Reminder Mailed | 24 Nov, 2025 | US8691871 |
Icosapent Ethyl's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Icosapent Ethyl:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia | Zhejiang Doer Biologics Co., Ltd. | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia | Ottawa Heart Institute Research Corporation | NA |
RECRUITING
(May 1, 2026)
| PHASE3 |